Lobular Carcinoma In Situ

What is Lobular Carcinoma In Situ?
Lobular Carcinoma in situ (LCIS) is not a breast cancer, but rather a high risk marker for
potential development of breast cancer in either breast in the future. Most lobular carcinoma in situ is diagnosed by a woman having a breast biopsy and is found at that time. Most women diagnosed with LCIS can be managed by close observation. However, the Breast Cancer Prevention Trial demonstrated that in a subgroup of women being followed with LCIS (826) risk was reduced by 56% by taking Tamoxifen.
In our practice, we follow women with Lobular Carcinoma In Situ closely at 6 month interval visits. We discuss options for chemoprevention or treatment with Tamoxifen, MRI, and lifestyle modification.